Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10–11
HOS-126848 · Präparat HOS-096317
In the neoadjuvant period of the BERENICE trial, the incidence of NYHA Class III/IV symptomatic LVD (congestive heart failure according to NCI-CTCAE v.4) was 1.5% in the group treated with dose dense doxorubicin and cyclophosphamide (AC) followed by Perjeta plus trastuzumab and paclitaxel and none of the patients (0%) experienced symptomatic LVD in the group treated with FEC followed 10 by Perjeta in combination with trastuzumab and docetaxel. The incidence of asymptomatic LVD (ejection fraction decrease according to NCI-CTCAE v.4) was 7% in the group treated with dose dense AC followed by Perjeta plus trastuzumab and paclitaxel and 3.5% in the group treated with FEC followed by Perjeta plus trastuzumab and docetaxel.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage b76b2ffdb84e26fa0f50655a547603c92c904dbcc51092c05b15411b10fbfda1 · Zeichen 8681–9501 im Abschnitt